ALKternate: A Proof of Concept Study in ALK-Rearranged NSCLC Alternating Lorlatinib With Crizotinib After Disease Progression

被引：0
|
作者：
Itchins, M. [1 ]
Liang, S. [1 ]
Brown, C. [2 ]
Solomon, B. [3 ]
Pavlakis, N. [1 ]
机构：
[1] Royal North Shore Hosp, Med Oncol, St Leonards, NSW, Australia
[2] Univ Sydney, Nhmrc Clin Trials Ctr, Camperdown, NSW, Australia
[3] Peter Maccallum Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
Drug resistance; ALK; Clinical trial;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P47.12
引用
收藏
页码：S1101 / S1102
页数：2
相关论文
共 50 条
  • [21] Sustained Response to Crizotinib After Resistance to First-Line Alectinib Treatment in Two Patients With ALK-Rearranged NSCLC
    Zheng, Jing
    Sun, Wenjia
    Chen, Wenhong
    Zhou, Jianying
    Zhou, Jianya
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (09) : E150 - E153
  • [22] Tumor Volume Analysis In ALK-Rearranged NSCLC Treated with Crizotinib: Identifying an Early Marker for Clinical Outcome
    Hida, T.
    Lydon, C.
    Hatabu, H.
    Johnson, B.
    Awad, M.
    Nishino, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S473 - S474
  • [23] Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib
    Ji, Jingran
    Mitra, Anupam
    Camidge, D. Ross
    Riess, Jonathan W.
    CLINICAL LUNG CANCER, 2021, 22 (06) : E851 - E855
  • [24] NVL-655 exhibits antitumor activity in lorlatinib-resistant and intracranial models of ALK-rearranged NSCLC
    Tangpeerachaikul, Anupong
    Deshpande, Amit
    Kohl, Nancy E.
    Horan, Joshua C.
    Pelish, Henry E.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [25] Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient
    Ai, Xinghao
    Niu, Xiaomin
    Chang, Lianpeng
    Chen, Rongrong
    Ou, Sai-Hong Ignatius
    Lu, Shun
    LUNG CANCER, 2018, 123 : 83 - 86
  • [26] Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib
    Zhu, Viola W.
    Cui, J. Jean
    Fernandez-Rocha, Maria
    Schrock, Alexa B.
    Ali, Siraj M.
    Ou, Sai-Hong Ignatius
    LUNG CANCER, 2017, 110 : 32 - 34
  • [27] Alectinib in ALK-Rearranged NSCLC Patients Following Crizotinib. Final Results and Biological Outcomes - Phase II ATALK Study
    Cortot, A.
    Escande, F.
    Gervais, R.
    Greillier, L.
    Corre, R.
    Veillon, R.
    Ionescu, M.
    Felicio, H.
    Pau, D.
    Gregoire, V.
    Girard, N.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S658 - S658
  • [28] Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First -Line Crizotinib-Treated ALK-Rearranged NSCLC
    Zhang, Yongchang
    Zeng, Liang
    Zhou, Chunhua
    Li, Yizhi
    Wu, Lin
    Xia, Chen
    Jiang, Wenjuan
    Hu, Yijuan
    Liao, Dehua
    Xiao, Lili
    Liu, Li
    Yang, Haiyan
    Xiong, Yi
    Guan, Rui
    Lizaso, Analyn
    Mansfield, Aaron S.
    Yang, Nong
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (06) : 1027 - 1036
  • [29] Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study
    Okauchi, Shinichiro
    Numata, Takeshi
    Nawa, Takeshi
    Ichimura, Hideo
    Saito, Takefumi
    Hayashihara, Kenji
    Yamada, Hideyasu
    Satoh, Hiroaki
    Endo, Takeshi
    Inage, Yoshihisa
    Kaburagi, Takayuki
    Kiyoshima, Moriyuki
    Yamada, Yutaka
    Tamura, Tomohiro
    Saito, Kazuhito
    Inagaki, Masaharu
    Hizawa, Nobuyuki
    Sato, Yukio
    Shiozawa, Toshihiro
    Sekine, Ikuo
    Ishikawa, Hiroichi
    Kurihima, Koichi
    Sakai, Mitsuaki
    Kamiyama, Koichi
    Kimura, Masaki
    Kikuchi, Norihiro
    Nakamura, Hiroyuki
    Furukawa, Kinya
    Kodama, Takahide
    Miyazaki, Kunihiko
    Yamashita, Takaaki
    Hayashi, Shigen
    Funayama, Yasunori
    Nomura, Akihiro
    ANTICANCER RESEARCH, 2020, 40 (02) : 957 - 964
  • [30] Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report
    Guisier, F.
    Piton, N.
    Bellefleur, M.
    Delberghe, N.
    Avenel, G.
    Angot, E.
    Vittecoq, O.
    Ould-Slimane, M.
    Morisse-Pradier, H.
    Salaun, M.
    Thiberville, L.
    BMC CANCER, 2020, 20 (01)
12345